Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TWST.

← Back to Free Index

TWST

Analysis as of: 2026-08-07

Twist Bioscience Corporation

Twist Bioscience manufactures synthetic DNA products, genomics tools, and antibody discovery inputs using a silicon-based DNA synthesis platform.

automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Strong Demand, Premium Price, Narrower Upside

A differentiated DNA manufacturing platform should keep compounding as AI increases biology workloads, but much of that opportunity is already reflected in valuation. The next leg of returns depends less on demand creation and more on proving durable profitability, pricing power, and post-dilution per-share value.

Analysis

Thesis

AI should expand the number of biological designs that must be physically built, and Twist owns a scaled DNA manufacturing stack that can capture part of that surge; if it converts more volume into trusted workflow share, contracted capacity, and durable margin gains, revenue can approach $1000M by 2031, though shareholder upside is capped unless profitability and dilution discipline become durable.

Last Economy Alignment

Cheaper AI-driven design should create more sequences to build, and Twist controls a real manufacturing bottleneck plus quality and security trust. The main limit is capture: if ordering becomes more price-transparent and agentic, volume can rise faster than margins.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

1.8x (from 5 most recent analyses)

Reasoning

The business can still compound well because AI increases biological design-build-test volume and Twist can sell more genes, genomics tools, and discovery inputs into the same accounts. But the stock already trades like a premium platform, so the likely path is revenue catching up to valuation rather than a dramatic rerating, unless Twist proves contract-like revenue quality and durable cash generation.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether AI creates more biology demand; it likely will. The real question is whether Twist captures that demand as durable economic value after dilution, supplier fragility, and premium expectations are accounted for. If ordering stays transactional, a strong factory can still produce only modest shareholder returns. If Twist converts reliability, speed, and security into stickier workflow economics, risk falls quickly.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Fiscal 2026 third-quarter revenue reached 118.4 and gross margin rose to 52.8, while full-year revenue guidance increased to 456-457 and the company reiterated Q4 adjusted EBITDA breakeven.
An August 2026 common-stock offering was proposed and then priced at an upsized 300, which reduced near-term liquidity risk but made dilution a realized event rather than a theoretical one.
The stock remained near its 52-week high despite the financing, showing that investors currently reward scale proof and TAM expansion more than they punish near-term dilution.

Thesis update

Operating proof improved, but the fresh capital raise shifted the equity debate from pure liquidity risk to whether post-dilution value capture can justify a still-premium setup. The core physical-bottleneck thesis is unchanged.

Forecast update

More of the turnaround is now reflected in the share price, so future return depends more on sustained profitability and cleaner revenue quality than on simple top-line growth.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.48

As AI designs more biological experiments, someone still has to build the DNA, and this company owns a scaled factory for that bottleneck. The upside comes from turning speed, quality, and trust into repeat contracts; the risk is that buying becomes too price-driven and reduces it to a better-run supplier.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$105.30

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research